Antibodies to CD40 with enhanced agonist activity

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10894835
APP PUB NO 20170253659A1
SERIAL NO

15195119

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
THE ROCKEFELLER UNIVERSITYNEW YORK NY 10065

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Dahan, Rony New York, US 11 23
Ravetch, Jeffrey V New York, US 56 572

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 19, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 19, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00